PCSA - Why Processa Pharmaceuticals Stock Is Soaring | Benzinga
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) shares are soaring Thursday after the company announced the completion of the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine.
The Details:
Processa said the data obtained from the Phase 1b trial has been used to select two dosage regimens for the Phase 2 trial which will be in advanced or metastatic breast cancer given the FDA’s agreement that the Phase 1b data can be used to ...